Journal
ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 3, Issue 2, Pages 153-159Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.6b00438
Keywords
biodistribution; intradermal; drug delivery; lymphatic
Categories
Funding
- National Institutes of Health (NIH) Grant [R01CA207619]
- NIH Cell and Tissue Engineering Training Grant [T32 GM008433]
- Clinical and Translational Science Award Program, NIH, National Center for Advancing Translational Sciences [UL1TR000454]
- National Science Foundation Award [1342194]
- Department of Defense Grant [CA150523]
Ask authors/readers for more resources
Therapeutic immunomodulation in the skin, its draining lymph nodes, or both tissues simultaneously using an intradermal administration scheme is desirable for a variety of therapeutic scenarios. To inform how drug carriers comprising engineered biomaterials can be leveraged to improve treatment efficacy by enhancing the selective accumulation or retention of payload within these target tissues, we analyzed the influence of particle versus macromolecule hydrodynamic size on profiles of retention in the site of dermal injection as well as the corresponding extent of accumulation in draining lymph nodes and systemic off-target tissues. Using a panel of fluorescently labeled tracers comprising inert polymers that are resistant to hydrolysis and proteolytic degradation that span a size range of widely used drug carrier systems, we find that macromolecule but not rigid particle retention within the skin is size-dependent, whereas the relative dermal enrichment compared to systemic tissues increases with size for both tracer types. Additionally, macromolecules 10 nm in hydrodynamic size and greater accumulate in draining lymph nodes more extensively and selectively than particles, suggesting that intra- versus extracellular availability of delivered payload within draining lymph nodes may be influenced by both the size and form of engineered drug carriers. Our results inform how biomaterial-based drug carriers can be designed to enhance the selective exposure of formulated drug in target tissues to improve the therapeutic efficacy as well as minimize off-target effects of locoregional immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available